Neuronetics Q3 2026 net loss narrows 83% to $1.56 million

• Neuronetics’ third-quarter 2026 net loss narrowed 83% year-over-year to $1.56 million.
• Total revenue rose 13% to $41.96 million, while Greenbrook revenue climbed 20% to $26.19 million year-over-year.
• Operating expenses fell 13% year-over-year to $21.35 million, primarily due to lower sales and marketing expenses.
• An accelerated TMS application remains under FDA review; a Wave Neuro agreement targets PTSD treatment, pending FDA clearance.
• FY26 revenue guidance remained $160 million–$164 million, while operating expense guidance fell to $92.5 million–$95.5 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuronetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040750PRIMZONEFULLFEED9869588) on November 04, 2026, and is solely responsible for the information contained therein.